




RealRate

PHARMACEUTICAL 2022

Kronos Bio Inc
Rank 143 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Kronos Bio Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kronos Bio Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 98% points. The greatest weakness of Kronos Bio Inc is the variable Research and Development, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 352%, being 77% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	347,554
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,626
Liabilities, Non-Current	32,753
Other Assets	43,922
Other Compr. Net Income	-20
Other Expenses	0
Other Liabilities	0
Other Net Income	320
Other Revenues	0
Property and Equipment	0
Research and Development	112,903
Selling, General and Administrative Expense	38,495

Output Variable	Value in 1000 USD
Assets	391,476
Liabilities	46,379
Expenses	151,398
Revenues	0
Stockholders Equity	345,097
Net Income	-151,078
Comprehensive Net Income	-151,088
BaseVar	294,796
ECR before Limited Liability	275%
Economic Capital Ratio	352%